Back to News
Market Impact: 0.1
Lilly To Present New Retatrutide, Taltz And Zepbound Data At ACR Convergence 2026
Source: Nasdaq
Healthcare & Biotech
Eli Lilly announced plans to present new clinical and real-world research on retatrutide, Taltz (ixekizumab) and Zepbound (tirzepatide) at ACR Convergence 2026. The article excerpt provides no study findings or additional conference details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
Ticker Sentiment
LLY0.25
More News
- HALOZYME REPORTS THIRD QUARTER 2026 RESULTS AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE
- We're booking big profits in 2 outperformers in Thursday's terrible market
- Cathie Wood’s ARK sells Broadcom stock, buys Nvidia and SpaceX
- We're raising our price target on Cardinal Health after another stellar quarter of profits
- Halozyme falls 6% as raised guidance fails to impress investors
- Dentsply earnings missed by $0.02, revenue fell short of estimates